A recent phase II trial of patients with metastatic prostate cancer demonstrated increased sensitivity of patients with ATM aberrations to a poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor [20]. This evidence concerns the gene ATM and metastatic prostate carcinoma.